STAT February 2, 2024
Usha Lee McFarling

The Food and Drug Administration should move more quickly to ensure pulse oximeters — the ubiquitous devices used to measure blood oxygen — work well in all patients, should better inform clinicians about the devices’ shortcomings in patients with darker skin, and should recall versions that are particularly problematic, patients, researchers, and consumer advocates testified during a public meeting on Friday.

The testimony occurred during an advisory panel meeting, held virtually to consider how to improve the safety of pulse oximeters, It comes more than three years after a study published at the height of the Covid-19 pandemic found that the devices didn’t detect low oxygen levels in some patients with darker skin, and after other studies showed the devices...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: FDA, Govt Agencies, Medical Devices
Opinion: STAT+: How will the Center for Biologics Evaluation and Research change under RFK Jr.?
How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder
FDA nominee pitches AI application review

Share This Article